Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
about
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future PerspectivesA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentResidual macrovascular risk in 2013: what have we learned?Nonalcoholic fatty liver disease: new treatmentsNuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Minireview: Challenges and opportunities in development of PPAR agonistsNew frontiers in the treatment of diabetic dyslipidemiaDual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Molecular Implications of the PPARs in the Diabetic Eye.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.PPARs and Mitochondrial Metabolism: From NAFLD to HCC.In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.New lipid-lowering drugs: an update.Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsEmerging drugs for non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Demystifying the management of hypertriglyceridaemia.Pharmacological agents for NASH.Critical review of non-statin treatments for dyslipoproteinemia.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Evolving therapies for non-alcoholic steatohepatitis.The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Pharmacological agents for nonalcoholic steatohepatitis.Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Management of NAFLD: a stage-based approach.Current and future treatment options in non-alcoholic steatohepatitis (NASH).Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Novel Pharmacotherapy Options for NASH.
P2860
Q26747009-5DDD0530-8E14-4D4E-99CB-36B662E86252Q26752487-BB644D80-164C-429F-BD85-4E297DA550C5Q26830274-C1445BB5-A55C-4DED-AA73-19DB3DB8B1F7Q26996039-3C49DE52-8A07-42BE-9675-696B15F46AC8Q27021161-E3963C9B-E4CB-40F6-8C06-3248A5FED148Q28066233-1DF43FF7-191A-4C6D-93F3-E848D641D5C8Q30241952-C47B32C8-18BB-4EB0-9B1B-5CC744A91A82Q33631921-970C9623-F62A-48B0-A438-0D58F27954A3Q33776236-42CE87C7-3A94-445B-8B1B-C570BA0E4F4CQ34036950-3DDDAFE7-FDBC-42C0-8253-6D76657BE2B2Q34041838-1179C7C2-67ED-4D28-B698-B69EE16E421FQ34041987-B7853917-D6B5-454F-A533-70E96B8B0856Q34398065-BDB3AE47-0453-431F-8241-8CC1D84DAFFEQ34594935-8CECD5BD-FB4B-49D9-B791-E0CEBC905FCFQ34647400-89E25046-345C-468C-AC21-1AE14CD5487CQ37563673-B49FC6A2-BCDC-4219-AA28-1877328791E5Q37575571-5CA0C0E4-2BE7-46F8-8FD5-2CA33B16D8A0Q37577126-0F9647AC-C03A-41CB-907E-E32C75BFC761Q37699483-883B2AAE-BA58-418D-8127-BDC28E9C9009Q37729625-4E849478-D9C2-42D4-B18B-6EB4CB4C4E1AQ37984782-5E582284-F234-41AF-9B0A-290FEFE3F409Q38076370-B6E68F89-6693-4528-94C2-1D3C03B56A0EQ38110581-B30CB495-EB0A-414C-94A8-2E36BF3FD3E2Q38121137-7905CCDF-EB3A-41E0-889F-7A268895BDDAQ38121574-23FA7875-3185-444F-A230-FEEB61BDE248Q38141575-A2BD0C24-DA06-437D-9C74-FC3F1AC8DDEBQ38152646-7055B1DE-15B8-4E4D-A4FF-552AC9E8D79AQ38186099-9041E9F6-A822-4E5E-97AD-1A9495E26BC2Q38201960-83B5C18E-5128-474F-9C86-833FA52FA9F1Q38207111-A11A8413-EBBB-4EA4-9DA4-0DA1EBAE49A4Q38273378-49F2586F-4864-40B7-AD62-A9D28D89568FQ38325814-9E707C3B-8B84-4737-A130-57BF74ED4AF3Q38552387-F2BD94D7-0A17-431D-8DB6-7EFD05F0EA2CQ38587721-E4EAD9ED-F510-48BD-A1D1-CC862D5489DCQ38674742-F05C5687-CCD1-413E-B60C-8C288FF6A51CQ38747405-F894EB35-2685-48A1-A748-167AF3027AA6Q38748381-E9D6BE78-C902-44AC-9C78-E8681E483600Q38778064-AC61008D-F6AA-449D-980B-6D6AD0F46477Q38782562-0E795059-70EE-4A42-8E43-C2D761E31648Q38784790-5588190A-A254-442D-AEB9-BA0489BF8119
P2860
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@ast
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@en
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@nl
type
label
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@ast
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@en
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@nl
prefLabel
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@ast
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@en
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@nl
P2093
P2860
P921
P356
P1433
P1476
Effects of the new dual PPAR α ...... r impaired glucose metabolism.
@en
P2093
Bertrand Cariou
Eric Bruckert
Yassine Zaïr
P2860
P304
P356
10.2337/DC11-0093
P407
P50
P577
2011-08-04T00:00:00Z